QULLA helps emerging, clinical-stage and virtual biotech companies build the right Quality Management System for their current development stage—without unnecessary bureaucracy or future remediation debt.
We assess the product lifecycle, operating model, outsourced activities and regulatory commitments before defining the required quality architecture. The result is a risk-based system that protects patients and asset value while enabling execution.
Quality controls should begin before regulated and outsourced activities create material product or data risk. The scope should grow with the programme rather than imitate a commercial pharmaceutical system from day one.
Yes. Engagements can combine executive-level direction with hands-on procedure development, governance setup, remediation and team coaching.
Explore all QULLA services · Read the Purple Papers · About Richard van Ewijk
We work with organizations where the stakes are high and quality excellence is non-negotiable — from advisory to hands-on execution.
Whether entering Phase I or scaling toward later-stage development, we help build quality infrastructure that matches ambition without overbuilding for the current stage.
We help CDMOs sharpen their quality positioning, strengthen governance structures, and demonstrate the operational robustness that clients and regulators demand.